This study looks at how safe and effective a new medicine, called NMD670, is for adults with Myasthenia Gravis (MG), a condition where the body's immune system attacks the connections between nerves and muscles, making them weak. The study will compare three different doses of NMD670 to a placebo, which is a treatment with no active medicine, over 21 days. People in the study will take the medicine twice a day.
- Participation Duration: 21 days, with twice-a-day doses.
- Eligibility: Adults 18 or older with MG and specific antibody tests, able to swallow pills.
- Exclusion: Certain medical conditions or recent experimental treatments may disqualify participation.
Participants must be able to understand and agree to the study, and they need to use contraception if needed. Both men and women can join, but women who are pregnant or breastfeeding cannot participate. It's important to be honest about health history to ensure safety during the study.
How understandable was the trial content above?
Hard to understand
Easy to understand